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Abstract
Background: Kidney stone disease has been associated with reduced kidney function and chronic kidney disease
(CKD). The objective of the study was to examine kidney function, body mass index (BMI) and the prevalence of
cardiovascular disease, hypertension and diabetes in recurrent kidney stone formers.
Methods: A cross-sectional, case-control study comparing measures of kidney function, BMI and comorbid conditions
was conducted in 195 kidney stone patients aged 18 to 70 years with recurrent clinical stone events and 390 age- and
gender-matched controls. Wilcoxon-Mann-Whitney, chi-square tests and analysis of covariance were used to compare
serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) between the groups.
Results: The median age of stone formers was 51 (range, 19–70) years and 108 (55 %) were males. Seventy patients
(36 %) had experienced 2–4 clinical stone events, 41 (21 %) 5–10 episodes and 84 (43 %) more than 10. The median
SCr was 75 (41–140) μmol/L in the stone formers and 64 (34–168) μmol/L in the control group (p < 0.001). The mean
eGFR was 87 ± 20 and 104 ± 22 mL/min/1.73 m2 in the stone formers and controls, respectively (p < 0.001).
After adjustment for body size and comorbid conditions, the difference in SCr and eGFR between cases and controls
remained highly significant (p < 0.001). The prevalence of CKD was 9.3 % among stone formers compared with 1.3 % in
the control group (P < 0.001). Hypertension and diabetes were significantly more prevalent among the cases that also
had higher BMI than controls.
Conclusions: Recurrent kidney stone formers have a significantly lower level of kidney function and a markedly higher
prevalence of CKD than age- and gender-matched control subjects. The observed deleterious effect of kidney stones
on kidney function appears to be independent of comorbid conditions.
Keywords: Chronic kidney disease, Diabetes, Hypertension, Nephrolithiasis, Obesity
Background
Kidney stone disease is a common chronic disorder
associated with painful stone episodes, lost work days
and significant health care costs [1], affecting up to
10–12 % of men and 5–6 % of women [2]. In recent
years, kidney stones have been associated with in-
creased risk of chronic kidney disease (CKD) [3], and
even end-stage renal disease (ESRD) [4, 5]. Further-
more, a number of studies have reported an increased
prevalence of cardiovascular disease [6], diabetes,
hypertension and obesity [7–9] in stone formers, sug-
gesting that kidney stone disease may be a systemic
disorder linked to the metabolic syndrome [7]. How-
ever, the independent contribution of kidney stone
disease to cardiovascular risk may be difficult to de-
tect as it may be mediated by other health conditions
such as CKD in the stone-forming population [10].
Although monogenic causes of nephrolithiasis fre-
quently result in ESRD [11], the relationship between
impaired kidney function and the common type of kid-
ney stones is much less clear. A few studies have sug-
gested at least a two-fold risk of CKD in subjects with
idiopathic calcium kidney stone disease [4, 12, 13].
Moreover, a retrospective case-control study based on
data from the Rochester Epidemiology Project found
stone formers to have a 51 % to 68 % increased risk for
a sustained elevation in serum creatinine (SCr) and for a
clinical diagnosis of CKD compared with non-stone formers
[3]. Another cross-sectional study showed a reduction in
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measured creatinine clearance in kidney stone clinic
patients compared with the general population [14].
Furthermore, in a report based on the Third National
Health and Nutrition Examination Survey (NHANES
III), obese stone formers had a modest decrease in
estimated glomerular filtration rate (eGFR) compared
with non-stone formers [15]. Finally, a recent study
carried out in England and Wales evaluating predic-
tors of CKD in a large cohort (n = 1,574,749) found
female stone formers to be at an increased risk of
moderate to severe CKD while no such risk was seen
in males [16]. However, an accurate characterization of
kidney stone patients and/or assessment of potential con-
founders, such as age-related decline in GFR and comor-
bid conditions, are lacking in the above-cited studies.
The objective of this study was to compare kidney
function, body mass index (BMI) and the prevalence of
cardiovascular disease, hypertension and diabetes in a
well-characterized population of Icelandic patients with
recurrent clinical stone events and an age- and gender-
matched control group from the general population.
Methods
Study design and setting
This was a cross-sectional, case-control study of 195
adult patients aged 18 to 70 years with recurrent kid-
ney stone disease. A written informed consent was
obtained from all participants in the study. The study
was approved by the National Bioethics Committee of
Iceland (NBC 03-002-V3) and the Icelandic Data Pro-
tection Authority.
Patient recruitment and characterization of kidney stone
disease
Patients with confirmed recurrent clinical stone disease
were recruited from two sources, the Kidney Stone Pre-
vention Clinic at Landspitali – The National University
Hospital of Iceland (LUH) in Reykjavik and the Icelandic
Kidney Stone Registry (IKSR) which was established in
2008 in conjunction with a nationwide study on kidney
stone disease [2]. Recurrent stone disease was defined as
a history of a minimum of two documented clinical
stone events, occurring at least 6 months apart to reduce
the probability of counting the same stone event more
than once. A clinical stone event was defined as either
acute flank pain associated with hematuria and/or the
detection of a stone by a medical imaging study, or a
patient-reported stone passage. In cases where a clin-
ical stone event was not confirmed by imaging, urinary
tract infection as a cause of acute flank pain was excluded.
All patients attending the LUH Kidney Stone Preven-
tion Clinic from December 2009 to January 2013 were
eligible for participation in the study. Records of all 144
patients who attended the clinic during this period were
reviewed. Of 99 patients who met the inclusion criteria,
95 agreed to participate. To increase the sample size, it
was decided to also include in the study patients from
the IKSR with a history of more than 2 clinical stone
events and a documented stone episode after January 1,
2002. Of a total of 287 eligible IKSR cases, 124 individ-
uals residing in the greater Reykjavik area were invited
to participate. Of these, 101 accepted the invitation; 16
did not reply and 7 declined. Hence, a total of 195 pa-
tients with recurrent kidney stone disease were included
in the study.
The presence of renal disorders other than kidney
stone disease was excluded by self-report (interview) and
thorough medical record review in all the cases, and by
searching the medical information systems at LUH for
all ICD-9 and ICD-10 codes suggestive of a specific kid-
ney disease. The above strategy led to the exclusion of
one patient with IgA nephropathy who developed stones
in a transplanted kidney, leaving the total number of
cases at 195. All study subjects were interviewed by two
of the investigators and underwent a brief physical
examination which included the evaluation of height,
weight and blood pressure. Current medication use was
recorded. To compare kidney stone patients with the
general population, a control group was drawn from a
cohort of 1,630 community-dwelling subjects aged 29–
87 years, who participated in a cross-sectional study of
bone health performed in Reykjavik in the years 2001–
2003 [17]. The participants in that study underwent a
thorough review of their medical history, measurement
of blood pressure and body composition, and laboratory
testing, including a single SCr measurement. For each
kidney stone patient, two controls were selected at ran-
dom from this cohort, excluding those with a history of
kidney stones. Since body composition and SCr are af-
fected by age and sex, both of which are included in
eGFR calculations, cases and controls were matched for
these factors. In addition, we compared the distribution
of BMI in our stone-forming sample with a group of
1,271 subjects from the general Icelandic population
using data from a nationwide study on nutrition con-
ducted by the Icelandic Directorate of Health for the
year 2011 (available at www.landlaeknir.is).
Evaluation of kidney function
All available SCr levels of kidney stone cases were ob-
tained from the electronic medical record system at
LUH, yielding a total of 3,320 values. SCr measurements
obtained during clinical stone episodes were excluded as
such events may cause acute kidney injury. The eGFR
was calculated by the MDRD study equation using the
lowest available SCr value within the last year of obser-
vation or SCr measured at least 3 months after a docu-
mented clinical stone event. CKD was defined as eGFR
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< 60 mL/min/1.73 m2. Two patients who only had a sin-
gle SCr value available obtained during an acute stone
event were excluded from the kidney function analysis
along with their corresponding controls. Only a single
SCr measurement was available for each control sub-
ject. All SCr values were IDMS-standardized and
measured at the clinical biochemistry laboratory at
LUH.
Stone composition
Results of stone analysis were retrieved from medical re-
cords and all available medical imaging reports were
reviewed in order to differentiate radiopaque from radio-
lucent stones. Stones visualized on a plain film of the
kidney, ureters and bladder were considered radiopaque
and were classified as calcium-containing stones.
Definition of comorbid conditions
Information on comorbid conditions was obtained
through medical history reported by the stone patients
and the controls, review of their medical records and/or
by searching for the appropriate ICD-9 and ICD-10
diagnostic codes for both cases and controls in the elec-
tronic patient information system at LUH. Hypertension
was defined as a history of hypertension diagnosed by a
physician and/or treatment with antihypertensive medi-
cations. Diabetes was defined as a history of a physician
diagnosed diabetes and/or treatment with antidiabetic
drugs. Cardiovascular disease was defined as evidence
for coronary artery disease, cerebrovascular disease or
peripheral vascular disease by ICD-9 (410–414, 430–438
and 440–448) and ICD-10 (I20-I25 and I60-I79) diag-
nostic codes suggestive of these disorders. The presence
of cardiovascular disease was further confirmed by re-
view of individual medical records.
Statistical analysis
Data are presented as mean ± standard deviation for nor-
mally distributed continuous variables and median
(range) for continuous variables that are not normally
distributed. Wilcoxon-Mann-Whitney, chi-square and
Fisher’s exact tests were used to compare stone formers
with controls and analysis of covariance (ANCOVA) to
compare the two groups with respect to SCr and eGFR,
adjusting for BMI, hypertension, diabetes and cardiovas-
cular disease which may affect the outcome variables.
The same methods were used to compare a subgroup of
patients with calcium stones with their corresponding
control subjects. Spearman’s correlation coefficient was
used to correlate the number of clinical stone events
with measures of kidney function. Statistical analysis was
performed with the computer software SPSS version 11
(SPSS, Chicago, IL).
Results
Characteristics of the 195 recurrent kidney stone for-
mers are outlined in Table 1. The median age was 51
(range, 19–70) years and 108 (55 %) were males. Seventy
patients (36 %) had experienced 2–4 clinical stone
events, 41 (21 %) had suffered 5–10 events and 84
(43 %) more than 10 stone events. A total of 154 pa-
tients (79 %) had radiopaque (calcified) stones and in 20
patients the stones were radiolucent. In the remaining
21 patients the radiological characteristics could not be
determined. Fifty-nine (30 %) patients had stones com-
posed of calcium oxalate but the stone composition was
unknown in more than half of the cases. Of 131 patients
(67 %) who underwent extracorporeal shock wave litho-
tripsy, 99, 18 and 10 required 1–4, 5–10 and > 10 treat-
ments, respectively. In addition, 2 patients required
open surgery for stone removal and 8 underwent percu-
taneous procedures. Finally, 80 patients had endoscopic
ureteral catheter insertion performed 1–4 times during
stone events and 4 patients on 5–10 occasions.
Table 2 shows the comparison of kidney function and
comorbid conditions between kidney stone patients and
Table 1 Clinical characteristics of kidney stone formers
Age at first stone episode, years 35 (15–67)
Number of stone episodes
2-4, N (%) 70 (36)
5-10, N (%) 41 (21)
>10, N (%) 84 (43)
Stone type (number of patients)
Radiopaque stones, N (%) 154 (79)
Calcium oxalate
Idiopathic, N 55
Hemicolectomy/gastric bypass, N 5
Calcium phosphate
Idiopathic, N 7
Primary hyperparathyroidism, N 3
Unknown, N 84
Radiolucent stones, N (%) 20 (10)
Uric acid, N 13
2,8-Dihydroxyadenine, N 2
Unknown, N 5
Not determined, N (%) 21 (11)
ESWL, N (%) 131 (67)
Insertion of ureteral catheter, N (%) 84 (43)
Stone removal surgery, N (%) 10 (5)
Percutaneous, N 8
Open, N 2
Data are presented as median (range) for continuous variables and as number
(%) for categorical variables
ESWL extracorporeal shock wave lithotripsy
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the control group. Cases and controls were almost exclu-
sively non-Hispanic Caucasians, which is representative of
the Icelandic population, and the control subjects were
carefully matched for age and sex. The median SCr was
75 (41–140) μmol/L in the stone formers and 64 (34–168)
μmol/L in the control group (p < 0.001). The mean eGFR
was 87 ± 20 and 104 ± 22 mL/min/1.73 m2 in the stone
formers and controls, respectively (p < 0.001). The preva-
lence of CKD was 9.3 % among stone formers compared
with 1.3 % in the control group (P < 0.001). All cases with
CKD had stage 3 disease and no difference between men
(9.4 %) and women (9.2 %) was observed (p = 0.96). The
number of clinical stone events and/or surgical stone re-
moval procedures did not correlate with either SCr or
eGFR. The prevalence of hypertension was significantly
higher among cases than controls (p = 0.003). The distri-
bution of BMI among stone formers was also significantly
different from the general population in the year 2011, as
34.4 % of stone formers had BMI > 30 kg/m2 compared
with 21.0 % of individuals in the general Icelandic popula-
tion and 19.5 % of the control subjects (p < 0.001).
Diabetes was more common among the cases, 7.7 %
vs 3.1 % (p = 0.02), whereas the prevalence of cardio-
vascular disease between the two groups was similar.
After adjustment for body size and comorbid condi-
tions, the observed difference in eGFR and SCr be-
tween cases and controls remained highly statistically
significant (p < 0.001, ANCOVA) as shown in Fig. 1.
A separate analysis was carried out for a subset of cal-
cium stone formers and their respective controls
(Table 3). Eight of the 154 calcium stone formers and
their corresponding control subjects were excluded from
the analysis because 3 had primary hyperparathyroidism
as the underlying cause of nephrolithiasis and 5 had a
past history of either gastric bypass surgery or hemico-
lectomy. For the remaining 146 cases, the median SCr
was 76 (41–140) μmol/L compared with 66 (39–168)
μmol/L in the control group (p < 0.001). The prevalence
of CKD was higher among stone formers than controls,
5.5 % vs 1.0 % (p = 0.008). After adjustment for body size
and comorbid conditions, the difference in SCr concentra-
tion and eGFR remained significant between the calcium
Table 2 Comparison of kidney function and comorbid






Age (years) 51 (19–70) 51 (29–71) -
Males, N (%) 108 (55.3) 216 (55.3) -
Serum creatinine (μmol/L)a 75 (41–140) 64 (34–168) < 0.001
eGFR (mL/min/1.73 m2)a 87.0 ± 20.3 104.0 ± 22.1 < 0.001
eGFR < 60 mL/min/1.73 m2a, N (%) 18 (9.3) 5 (1.3) < 0.001
BMI (kg/m2) 28.1 (17.0-49.1) 26.0 (17.4-45.3) < 0.001
Systolic BP (mm Hg) 130 (86–175) 131 (90–212) 0.51
Diastolic BP (mm Hg) 78 (38–108) 81 (54–122) 0.001
Hypertension, N (%) 65 (33.3) 86 (22.1) 0.003
Diabetes, N (%) 15 (7.7) 12 (3.1) 0.02
Cardiovascular disease, N (%) 10 (5.1) 28 (7.2) 0.34
Data are presented as mean ± standard deviation for normally distributed
variables, median (range) for other continuous variables and as number (%) for
categorical variables
Abbreviations: BMI body mass index, BP blood pressure, eGFR estimated
glomerular filtration rate
aTwo cases with only a single serum creatinine value available during a stone
episode and the corresponding controls were excluded
Fig 1 Adjusted mean eGFR in the kidney stone patients and the
control group. The bars represent 95 % confidence intervals
Table 3 Comparison of kidney function and comorbid
conditions between idiopathic calcium stone formers and
controls
Calcium stone




Age (years) 50 (19–70) 51 (29–71) -
Males (%) 83 (56.8) 166 (56.8) -
Serum creatinine (μmol/L)a 74 (41–131) 66 (39–168) < 0.001
eGFR (mL/min/1.73 m2)a 87.1 ± 18.9 103.8 ± 21.0 < 0.001
eGFR < 60 mL/min/1.73 m2a, N (%) 8 (5.5) 3 (1.0) 0.008
BMI (kg/m2) 27.9 (17.0-49.1) 26.0 (17.7-45.3) < 0.001
Systolic BP (mm Hg) 129 (86–175) 130 (93–212) 0.28
Diastolic BP (mm Hg) 78 (47–108) 81 (54–122) 0.001
Hypertension, N (%) 44 (30.1) 59 (20.2) 0.02
Diabetes, N (%) 9 (6.2) 8 (2.7) 0.08
Cardiovascular disease, N (%) 7 (4.8) 19 (6.5) 0.48
Data are presented as mean ± standard deviation for normally distributed
variables, median (range) for other continuous variables and as number (%) for
categorical variables
Abbreviations: BMI body mass index, BP blood pressure, eGFR estimated
glomerular filtration rate
aOne case with only a single serum creatinine value available during a stone
episode and the corresponding control were excluded
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stone formers and their controls (p < 0.001, ANCOVA).
No correlation was found between the number of
stone episodes and/or surgical stone removal proce-
dures and SCr or eGFR in the calcium stone formers.
The prevalence of hypertension and elevated BMI was
significantly higher among calcium stone formers than
controls, while the prevalence of diabetes and cardio-
vascular disease was not statistically different between
the two groups (Table 3).
Of the 18 patients with confirmed radiolucent stones,
2 patients with adenine phosphoribosyltransferase
(APRT) deficiency were excluded. Of the remaining 16
patients, 7 (44 %) had CKD compared with none of the
corresponding control subjects (p < 0.001). The preva-
lence of CKD was also significantly higher among the
patients with radiolucent stones compared with calcium
stone formers (p < 0.001).
Discussion
In the present study, we found a significantly lower level
of kidney function and a markedly higher prevalence of
CKD in patients with recurrent kidney stone disease
than in age- and gender-matched control subjects.
Nearly identical results were observed in the subset of
idiopathic calcium stone formers. Moreover, kidney
stone disease associated with obesity, hypertension and
diabetes but not with established cardiovascular disease.
The observed deleterious effect of stone disease on kid-
ney function was independent of these comorbid
conditions.
Adverse renal outcomes, ranging from modest reduc-
tion in kidney function [14] to established CKD [3] and
even ESRD [4, 18], have previously been reported in pa-
tients with the common type of kidney stone disease.
However, earlier studies have shown conflicting results.
For example, in a large study based on data from
NHANES III [15] the observed mild eGFR reduction
was limited to obese stone formers, while in another
study the increased CKD risk in kidney stone patients
was limited to the female gender [16]. Worcester et al.
[14], reported a significantly lower measured creatinine
clearance adjusted for age, gender and body weight in
1856 US kidney stone formers followed at the University
of Chicago compared with that of 153 normal individ-
uals. Even though these authors did not correct for co-
morbid disorders, their results are in agreement with
our findings. As in the current study, the average reduc-
tion in kidney function in the Chicago study was modest
and the observations among calcium stone formers were
similar to ours. Data on the prevalence of CKD were not
reported for the Chicago cohort.
In our study, approximately 9 % of all kidney stone pa-
tients and 6 % of calcium stone formers had CKD, which
is approximately 6 to 7 times higher than in the control
group. These results contrast with findings of other re-
cent studies showing stone formers to be at an approxi-
mately twofold risk of CKD [4, 12, 13] or even less [3].
We speculate that disease severity may have contributed
to the increased CKD risk in our study since a large pro-
portion of the cases had a history of both multiple
stone events and stone removal procedures. Also, a
low prevalence of CKD in the control group may
have influenced this finding to some extent, although
in these relatively young individuals the prevalence of
eGFR < 60 mL/min/1.73 m2 is expected to be low
[19]. The exclusion of all SCr measurements obtained
during the first 3 months following a clinical stone
event and the selection of the lowest available SCr
value within the last year of available measurements
for our eGFR calculations likely biased our results to-
wards a lower CKD risk in stone formers when com-
pared to previous work in this field, adding further
strength to our findings. Interestingly, no correlation
was observed between the number of stone events
and/or surgical stone removal procedures and kidney
function in our study. In contrast, a recent Canadian
cohort study showed an augmentation of the CKD
risk in patients with more than one clinical stone
event compared with single stone formers [4]. How-
ever, these findings are not directly comparable to the
results of our study in which all subjects had recur-
rent stone disease.
The degree of kidney injury associated with nephro-
lithiasis has been reported to vary for different stone
types. We observed a significantly worse renal outcome
in patients with radiolucent stones compared with other
types of kidney stones. In the aforementioned study by
Worcester et al., stone type was predictive of the level of
kidney function which was lowest in patients with cystin-
uria followed by uric acid stone formers [14]. The in-
vestigators demonstrated that patients with uric acid
stones had a lower measured creatinine clearance
compared with brushite (calcium monohydrogen phos-
phate) and calcium oxalate stone formers and normal
control subjects, and patients with stones composed of
calcium oxalate, calcium apatite or struvite all had less
kidney function than normal controls.
The pathogenesis of CKD in patients with kidney
stone disease likely involves multiple different pathways
[3, 20]. Obstruction to urine flow caused by stones has
the potential to inflict kidney injury. In fact, unilateral
ureteral obstruction, which in animal models has been
shown to cause intense renal vasoconstriction and renal
blood flow reduction, can lead to significant ischemia
and permanent renal parenchymal damage [21]. Renal
parenchymal crystal deposition and the associated in-
flammation and fibrosis have been well described in pa-
tients with primary hyperoxaluria and APRT deficiency
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[11] and similar histological changes have also been ob-
served in patients with uric acid and struvite stones [10].
Furthermore, Evan et al. [22] have elegantly shown that
obstruction of the ducts of Bellini, commonly seen in
brushite stone formers, is strongly associated with tubu-
lar atrophy, interstitial fibrosis and glomerulosclerosis
[23]. While crystal nephropathies can cause inflamma-
tion and fibrosis leading to severe kidney damage, the
underlying pathobiological mechanisms of CKD in or-
dinary human kidney stone disease remain elusive. In
animal models, however, the best characterized pathway
of calcium oxalate crystal-induced inflammation involves
NLRP3 inflammasome-mediated mechanisms, leading to
direct injury to tubular cells, neutrophil recruitment,
tubulointerstitial inflammation and progressive renal
failure [15, 24].
In our study the prevalence of obesity, hypertension
and diabetes was higher in stone formers than in the
control group. The increased prevalence of these fea-
tures of the metabolic syndrome in stone formers has
previously been reported [3, 9, 15, 25]. While hyperten-
sion and diabetes are well known risk factors for CKD,
the negative impact of stone disease on kidney function
occurred independently of these comorbid conditions.
These findings are in concert with those of a recent
study that associated metabolic syndrome trait clustering
with a greater severity of kidney stone disease and urine
chemistry risk factors [7].
Strengths of the current study include the well-defined
study population of recurrent stone formers and high
participation rate. In addition, by using the lowest SCr
in the last year of observation for each patient and ex-
cluding from the analysis those who did not have a
follow-up SCr measurement available after an acute
stone event, we may have avoided an overestimation of
CKD prevalence in stone formers. Moreover, cases with
another known underlying cause of CKD were excluded
from the study sample and two age- and gender-matched
subjects were used to control for age-related decline in
kidney function. Furthermore, since all emergency and in-
patient care in the greater Reykjavik area is centralized at
a single institution, complete medical records were avail-
able for all cases and controls allowing the assessment of
all major stone events and significant comorbid condi-
tions. Finally, as the study participants were almost exclu-
sively non-Hispanic Caucasians our results are likely to be
generalizable to the white population living in Europe and
North America. The main limitations of the study are a
relatively small sample size and the lack of information on
stone composition in a significant number of study sub-
jects. Other limitations include potential sources of bias
related to ascertainment of variables known to affect kid-
ney function and its estimation. However, by exclud-
ing stone patients with other underlying kidney
diseases and SCr values obtained during stone epi-
sodes and by using the lowest SCr available in the
last year of observation for each patient, we believe we
have avoided overestimation of CKD. To the contrary,
the prevalence of CKD in kidney stone patients may
have been underestimated. Finally, the definition of a
clinical stone event as acute flank pain associated
with hematuria without confirmation by imaging can
be considered a limitation. However, the fact that all
patients included in the study had recurrent kidney
stone disease confirmed by a physician and a number
of imaging studies carried out during the course of
their disease makes other diagnoses unlikely.
Conclusions
Patients with recurrent kidney stone disease experience
a decline in kidney function over time and have a signifi-
cantly higher prevalence of CKD than age- and gender-
matched control subjects. Furthermore, the negative im-
pact of stone disease on kidney function is greatest in
patients with radiolucent stones. Although obesity,
hypertension and diabetes were more frequent among
patients than controls, the observed reduction in kidney
function and the higher prevalence of CKD appears to
be independent of these comorbid conditions. Recurrent
stone formers should receive care and follow-up in a
multidisciplinary kidney stone clinic. Prospective long-
term outcome studies are needed to better define the
association between kidney stone disease and adverse
renal outcomes.
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